


A compound effective against chemotherapy-resistant cancer cells identified

October 18 2019



The administration of the compound 10580 caused human GICs (red) transplanted in mice to undergo apoptosis, a type of cell death (green). Credit: Hokkaido University

A compound effective in killing chemotherapy-resistant glioblastoma-initiating cells (GICs) has been identified, raising hopes of producing drugs capable of eradicating refractory tumors with low toxicity.

Despite longstanding and earnest endeavors to develop new remedies, the prognosis of most [glioblastoma](#) patients undergoing chemotherapies and radiotherapies remains poor. Glioblastoma, a malignant glioma, has a median survival period of approximately 15 months. One of the reasons for this is the lack of methods to eradicate its [cancer stem cells](#), or glioblastoma-initiating cells (GICs), that demonstrate tumorigenicity (ability to form tumors) and resistance to chemotherapies and radiotherapies.

In a study published in *Neuro-Oncology*, the collaborative research group between Hokkaido University, FUJIFILM Corporation, and the National Institute of Advanced Industrial Science and Technology (AIST) successfully cultured human GICs resistant to temozolomide (TMZ), a standard [drug](#) used for treating glioblastoma. Next, using Fujifilm's compound library, they conducted a high-throughput drug screening to identify a compound that can specifically kill or inflict damage to GICs, not normal cells such as neural stem cells and astrocytes. The efficacy of the candidate [compounds](#) was examined using cytotoxic activities, expressions of various cell markers, and tumor-suppressive activities as indicators.

Compound 10580 was successfully identified as being capable of killing or inflicting damages to GICs. The research group identified that the compound inhibited the activity of dihydroorotate dehydrogenase (DHODH), an essential enzyme for pyrimidine synthesis found in the mitochondria's inner membrane.

While analyzing the compound's efficacy, it was also discovered that the compound decreased the expression of stem cell factors in GICs,

unraveling a part of its molecular mechanism. Moreover, the compound was orally administered to tumor-bearing mice, which confirmed its strong anti-cancer efficacy. The mice exhibited no visible toxicity, suggesting that the compound is non-toxic to normal [cells](#).

"Compound 10580 is a promising candidate for developing drugs against glioblastoma and other recurring cancers. Further technological developments of a drug delivery system or 10580 derivatives, which can cross the [blood-brain barrier](#), are needed," says Toru Kondo of Hokkaido University's Institute for Genetic Medicine who led the study.

More information: Echizenya et al. Discovery of a new pyrimidine synthesis inhibitor eradicating glioblastoma-initiating cells, *Neuro-Oncology* (2019). [DOI: 10.1093/neuonc/noz170](https://doi.org/10.1093/neuonc/noz170)

Provided by Hokkaido University

Citation: A compound effective against chemotherapy-resistant cancer cells identified (2019, October 18) retrieved 5 May 2024 from <https://medicalxpress.com/news/2019-10-compound-effective-chemotherapy-resistant-cancer-cells.html>

| |
|---|
| This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only. |
|---|